Summary
Nursing home-acquired pneumonia (NHAP) is a diagnostic and therapeutic challenge, and antimicrobial therapy represents only 1 facet of the treatment of this disease. The nursing home population consists of a mixture of well, frail and dependent elderly. For some residents, supportive care may be the best therapeutic option.
A variety of antimicrobial regimens have been proposed for the empirical therapy of NHAP; however, there are still very few data from controlled clinical trials that assess outcome. The clinical trials that have been completed support the concept that an early switch from intravenous to oral therapy can be successfully used to treat pneumonia affecting frail, often seriously ill, groups of patients.
Annual influenza vaccine should be offered to all nursing home residents. This practice is about 50% effective in preventing hospitalisation and pneumonia, and about 80% effective in preventing death. The same level of evidence is not available to support the use of pneumococcal vaccine in this group; however, current practice suggests that all nursing home residents receive this vaccine on admission and once every 6 years thereafter.
Frequently, knowledge about pneumonia is not applied as optimally as should be done. Care maps have been shown to reduce length of stay and shorten the time from emergency room entry until administration of antibiotic therapy by up to 3 hours.
Areas for urgent research attention in patients with NHAP are: (a) proper studies to define the microbiological aetiology of NHAP (this requires bron-choscopy with sampling of the distal airways using a protected bronchial brush); (b) randomised controlled clinical trials of sufficient size to determine whether one antibiotic regimen is superior to another (currently most trials are designed to show that the agent under study is equivalent to a currently used agent); and (c) end-of-life decision making in the nursing home population.
Similar content being viewed by others
References
Olive KE, Berk SL. Infection in the nursing home. Clin Geriatr Med 1992; 8: 821–34
Marrie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect 1990; 5: 260–8
Marrie TJ, Durant J, Kwan C. Nursing home-acquired pneumonia: a case-control study. J Am Geriatr Soc 1986; 34: 697–702
Garb JL, Brown RB, Garb JR, et al. Differences in etiology of pneumonias in nursing home and community patients. JAMA 1978; 240: 2169–72
Marrie TJ, Durant H, Yates L. Community acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989 Jul-Aug; 11(4): 586–99
Phillips SL, Branaman-Phillips J. The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia. J Am Geriatr Soc 1993; 41: 1071–4
Drinka PJ, Gauerke C, Voeks S, et al. Pneumonia in a nursing home. J Gen Intern Med 1994; 9: 650–2
Chow CW, Senathiragah N, Rawji M, et al. Interim report on drug utilization review of community-acquired and nosoco-mial pneumonia: clinical bacteriological and radiological spectrum. Can J Infect Dis 1994; 5 Suppl. C: 20C–27C
Morris J. Physiological changes due to age: implications for respiratory drug therapy. Drugs Aging 1994; 4(3): 207–20
Holas MA, DePippo KL, Reading MJ. Aspiration and relative risk of medical complications following stroke. Arch Neurol 1994; 51: 1501–3
Kilkuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251–3
Horner J, Alberts MJ, Davison DN, et al. Swallowing in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1994; 8: 177–89
Fein AM. Pneumonia in the elderly: special diagnostic and therapeutic considerations. Med Clin North Am 1994 Sep; 78: 1015–33
Terpenning MS, Bradley SF, Wan JY, et al. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 1994; 42: 1062–9
Valenti WM, Trudel RG, Bentley DW. Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med 1978; 298: 1108–11
Falsey AE, Treanor JJ, Betts RF, et al. Viral respiratory infections in the institutionalized elderly: clinical and epidemio-logic findings. J Am Geriatr Soc 1992; 40: 115–9
Mehr DR, Foxman B, Colombo P. Risk factors for mortality from lower respiratory infections in nursing home patients. J Fam Pract 1992; 34: 585–91
Ainslie N, Beisecker AE. Changes in decisions by elderly persons based on treatment description. Arch Intern Med 1994 Oct 10; 154: 2225–33
Tresch DD, Neahring JM, Duthie EH, et al. Outcomes of car-diopulmonary resuscitation in nursing homes: can we predict who will benefit?. Am J Med 1993; 95: 123–30
Tsevan J, Cook F, Green ML, et al. Health values of the seriously ill. Ann Intern Med 1994; 122: 514–20
British Thoracic Society and Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987; 62: 195–220
Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994; 9: 140–52
Norman DC. Pneumonia in the elderly: empiric antimicrobial therapy. Geriatrics 1991 Dec; 46: 26–32
Mulligan T. Parenteral antibiotic therapy for patients in nursing homes. Rev Infect Dis 1991; 13 Suppl. 2: S180–3
Mandell LA, Niederman M, The Canadian Community Acquired Pneumonia Consensus Conference Group. Antimicrobial treatment of community-acquired pneumonia in adults: a conference report. Can J Infect Dis 1993 Jan/Feb; 4(1): 25–8
Lefevre F, Feinglass J, Potts S, et al. Iatrogenic complications in higher-risk, elderly patients. Arch Intern Med 1992 Oct; 152: 2074–80
Esposito AL. Pneumonia in the elderly. Am Fam Physician 1989; 40 Suppl. 5: 23S–32S
Donowitz GR, Mandell GL. Drug therapy: betalactam antibiotics (1). N Engl J Med 1988; 318(7): 419–26
Donowitz GR, Mandell GL. Drug therapy: betalactam antibiotics (2). N Engl J Med 1988; 318(8): 490–500
Mandigers CMPW, Diepersloot RJA, Dessens M, et al. A hospital outbreak of penicillin-resistant pneumococci in the Netherlands. Eur Respir J 1994; 7: 1635–9
Mandell LA. Antibiotics for pneumonia therapy. Med Clin North Am 1994 Sep; 78(5): 997–1013
Goldstein EJC, Citron DM. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococ-cus epidermidis, and methicillin-susceptible and resistant and tolerant and non-tolerant Staphylococcus aureus. Antimicrob Agents Chemother 1985 Jul; 28(1): 160–2
Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP 1991; 25: 546–52
Choo U. UK revises indications for co-trimoxazole. Lancet 1995 Jul 15; 346: 175
Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4(2): 145–73
Peterson PK, Stein D, Guary DRP, et al. Prospective study of lower respiratory tract infections in an extended care nursing program: potential role of oral ciprofloxacin. Am J Med 1988 Sep; 65: 164–70
Pickering TD, Gurwitz JH, Zaleznik D, et al. The appropriateness of oral fluoroquinolone-prescribing in the long-term care setting. J Am Geriatr Soc 1994; 42: 28–32
Saltiel E, Weingarten S. Drug treatment of pneumonia in the elderly: efficacy and costs. Pharmacoeconomics 1993; 3(4): 268–75
Wilson WR. Tolerance and safety of orally administered antimicrobial agents: an important factor in the selection of drug therapy. Curr Ther Res 1994; 55 Suppl. A: 49–56
Guay DRP. Sequential antimicrobial therapy: a realistic approach to cost containment. Pharmacoeconomics 1993; 3(5): 341–4
Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. Chest 1994; 105: 1109–15
Ehrenkranz NJ, Nerenberg DE, Shultz JM, et al. Intervention to discontinue parenteral antimicrobial therapy in patients hospitalized with pulmonary infections: effect on shortening patient stay. Infect Control Hosp Epidemiol 1992; 13: 21–32
Hirta-Dulas CAI, Stein DJ, Guay DRP, et al. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home acquired lower respiratory tract infections. J Am Geriatr Soc 1991; 39: 979–85
Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273–6
Trenholme GM, Scmitt BA, Spear J, et al. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med 1989; 87 Suppl. 5A: 116S–8S
Dunagan WC, Woodward RS, Medoff G, et al. Antimicrobial misuse in patients with positive blood cultures. Am J Med 1989; 87: 253–9
Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307
Ortiz CR, LaForce FM. Prevention of community-acquired pneumonia. Med Clin North Am 1994 Sep; 78(5): 1173–83
Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly patients. Ann Intern Med 1995; 123: 518–27
Makela PH, Jokinen C, Pyhala R, et al. Use of vaccines for respiratory infections: strategies for influenzae and pneumo-coccal vaccines. Scand J Infect Dis 1990; Suppl. 70: 141–8
Fox RA. Treatment recommendations for respiratory tract infections associated with aging. Drugs Aging 1993; 3(1): 40–8
Anonymous. Appropriate treatment of pneumonia in the elderly may reduce costs. Drugs Ther Perspect 1993 Aug 30; 2(4): 14–6
Butler JC, Breiman FR, Campbell JF, et al. Pneumococcal poly-saccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270: 1826–31
Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84
Woo J, Ho SC, Mak YT, et al. Nutritional status of elderly patients during recovery from chest infection and the role of nutritional supplementation assessed by a prospective randomized single-blind trial. Age Ageing 1994; 23: 40–8
Hunt C, Chakravorty NK, Annan G, et al. The clinical effects of vitamin C supplementation in elderly hospitalized patients with acute respiratory infections. Int J Vitam Nutr Res 1994; 64: 212–9
Nelson S, Summer W, Bogby G, et al. Granulocyte colony-stimulating factor enhances pulmonary host defences in normal and ethanol treated rats. J Infect Dis 1991; 164: 901–6
Lester P, Gentry M, Prehein L. Granulocyte colony-stimulating factor protects control rats but not ethanol-fed rats from fatal pneumococcal pneumonia. J Infect Dis 1993; 168: 922–6
Sperry S, Birdsall C. Outcomes of a pneumonia critical path. Nurs Econ 1994; 12: 332–45
Esler R, Bentz P, Sorensen M, et al. Patient-centred pneumonia care: a case management success story. Am J Nurs 1994; 94: 34–8
Rollins D, Thomasson C, Sperry B. Improving antibiotic delivery time to pneumonia patients: continuous quality improvement in action. J Nurs Care Qual 1994; 8: 22–31
May HM, Harrison TS, Harrison BDW. A criteria based audit of community-acquired pneumonia. Respir Med 1994; 88: 693–6
Jolley AE, Davies AJ, McLeod DT. Audit of the use of erythro-mycin in the treatment of community-acquired lower respiratory tract infections. Respir Med 1992; 86: 503–5
Dempsey CJ. Nursing home-acquired pneumonia: outcomes from a clinical process improvement program. Pharmacother-apy 1995; 15(1 Pt 2): 33S–8S
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marrie, T.J., Slayter, K.L. Nursing Home-Acquired Pneumonia. Drugs & Aging 8, 338–348 (1996). https://doi.org/10.2165/00002512-199608050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199608050-00003